Drug intelligence / Profile preview

Omni-Biotic Hetox

Development stage: Unknown
Lead developer: Institut AllergoSan
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Omni-Biotic Hetox is a multi-strain probiotic dietary supplement developed by the Austrian company Institut Allergosan. It is formulated with 8 to 9 specifically selected bacterial strains from the *Lactobacillus*, *Bifidobacterium*, and *Lactococcus* genera, providing 15 billion CFU per dose. The product is designed to support liver function and detoxification via the gut-liver axis. Its mechanism involves strengthening the intestinal barrier to reduce the translocation of pro-inflammatory endotoxins into the portal circulation, thereby alleviating the toxic load on the liver. Clinical studies have investigated its efficacy in patients with type 2 diabetes and liver cirrhosis, demonstrating improvements in liver enzymes, glucose metabolism, cholesterol levels, and systemic cardiometabolic parameters.

Brand names: OMNi-BiOTiC HETOX
Other names: Omni-Biotic Hetox

Beyond the preview

Go deeper on Omni-Biotic Hetox.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Omni-Biotic Hetox.

Explore the full profile